History of CD38 antibodies. The timeline describes the discovery of CD38 protein, and the chronological introduction of CD38 antibodies in human trials. The timeline also shows the approved treatment options with CD38-targeted therapy in MM. DPd, daratumumab plus pomalidomide-dexamethasone; DRd, daratumumab plus lenalidomide-dexamethasone; DVd, daratumumab plus bortezomib-dexamethasone; EMA, European Medicines Agency; FDA, US Food and Drug Administration; IMiD, immunomodulatory drug; Pd, pomalidomide-dexamethasone; PI, proteasome inhibitor; Rd, lenalidomide-dexamethasone; Vd, bortezomib-dexamethasone.